{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:25:01Z","timestamp":1770884701618,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.leukres.2012.02.027","type":"journal-article","created":{"date-parts":[[2012,3,28]],"date-time":"2012-03-28T01:47:06Z","timestamp":1332899226000},"page":"664-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evolution of clinical trial endpoints in chronic myeloid leukemia: Efficacious therapies require sensitive monitoring techniques"],"prefix":"10.1016","volume":"36","author":[{"given":"Raoul","family":"Tibes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2012.02.027_bib0005","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0010","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1309\/AJCPUN89CXERVOVH","article-title":"Chronic myelogenous leukemia, BCR-ABL1+","volume":"132","author":"Vardiman","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0015","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0020","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.02.027_bib0025","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0030","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.02.027_bib0035","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.02.027_bib0040","first-page":"1","article-title":"The ongoing evolution of clinical endpoints in oncology","volume":"19","author":"McCain","year":"2010","journal-title":"Manag Care"},{"key":"10.1016\/j.leukres.2012.02.027_bib0045","unstructured":"Food and Drug Administration. Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics, 2007. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm071590.pdf [accessed 26.06.11]."},{"key":"10.1016\/j.leukres.2012.02.027_bib0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"Response definitions and European LeukemiaNet Management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0055","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Chronic Myelogenous Leukemia (Version 2.2012). \u00a9 2012 National Comprehensive Cancer Network, Inc. Available at: NCCN.org."},{"key":"10.1016\/j.leukres.2012.02.027_bib0060","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2009-02-163485","article-title":"How I monitor residual disease in chronic myeloid leukemia","volume":"114","author":"Radich","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.02.027_bib0070","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.21457","article-title":"Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia","volume":"84","author":"Foroni","year":"2009","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.leukres.2012.02.027_bib0075","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0080","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.02.027_bib0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0090","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V82.2.398.398","article-title":"Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group","volume":"82","author":"Hehlmann","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0095","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia","volume":"330","author":"Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.02.027_bib0100","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V86.3.906.906","article-title":"A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase","volume":"86","author":"Ohnishi","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0105","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2012.02.027_bib0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0115","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2012.02.027_bib0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2012.02.027_bib0125","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.26249","article-title":"Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase","volume":"118","author":"Nicolini","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2012.02.027_bib0135","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2009.156","article-title":"Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2012.02.027_bib0140","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2012.02.027_bib0145","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive CML patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0150","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0155","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0160","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1182\/blood.V116.21.3427.3427","article-title":"Nilotinib 300mg twice daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: updated results of the ICORG 0802 phase 2 study with analysis of the GeneXpert system versus IS BCR-ABL RQ PCR","volume":"116","author":"Conneally","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0165","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0170","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0175","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.LBA-6.LBA-6","article-title":"A randomized phase II trial of dasatinib 100mg vs imatinib 400mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 intergroup trial","volume":"116","author":"Radich","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0180","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood.V116.21.206.206","article-title":"Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up","volume":"116","author":"Shah","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0185","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood.V116.21.208.208","article-title":"An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia","volume":"116","author":"Gambacorti-Passerini","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0190","first-page":"6509","article-title":"Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up","volume":"29","author":"Gambacorti-Passerini","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.leukres.2012.02.027_bib0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood.V116.21.207.207","article-title":"ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0200","first-page":"6510","article-title":"Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): two-year follow-up from DASISION","volume":"29","author":"Kantarjian","year":"2011","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.leukres.2012.02.027_bib0205","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2012.02.027_bib0210","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon versus STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0215","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0220","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800mg\/d versus 400mg\/d versus 400mg\/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0225","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.02.027_bib0230","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.21850","article-title":"Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter?","volume":"85","author":"Kim","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0235","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood.V118.21.3784.3784","article-title":"Kinetics of molecular response with different tyrosine kinase inhibitors (TKI) used as frontline therapy in chronic myeloid leukemia-chronic phase (CML CP)","volume":"118","author":"Naqvi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0240","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood.V118.21.2767.2767","volume":"118","author":"Hochhaus","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0245","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.V118.21.783.783","article-title":"Molecular and cytogenetic response after 3months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients\u2014a follow-up analysis of the German CML Study IV","volume":"118","author":"Hanfstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0250","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0255","series-title":"16th Congress of the European Hematology Association (EHA)","article-title":"Cessation of dasatinib or nilotinib therapy in chronic-phase chronic myeloid leukaemia patients with sustained complete molecular responses","author":"Rea","year":"2011"},{"key":"10.1016\/j.leukres.2012.02.027_bib0260","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3324\/haematol.2011.048165","article-title":"Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features","volume":"96","author":"Ross","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2012.02.027_bib0265","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0270","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2012.02.027_bib0275","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2012.02.027_bib0280","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612000999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212612000999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:57:39Z","timestamp":1758934659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212612000999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0145212612000999"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2012.02.027","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of clinical trial endpoints in chronic myeloid leukemia: Efficacious therapies require sensitive monitoring techniques","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2012.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}